For results for completed and on-going clinical trials in ovarian cancer for all drugs in a specific category, click on the drug category (e.g., Angiogenesis Inhibitors) on the left. To see only results for specific drugs in a class, click on the drug class for the drugs that interest you. For a schematic diagram of cell growth and survival pathways that these drugs inhibit, please scroll to the bottom of the page.

DNA DAMAGE REPAIR PATHWAY INHIBITORS PARP (Poly ADP-ribose Polymerase) Niraparib (Zejula™)
Olaparib (Lynparza™)
Rucaparib (Rubraca™)
Talazoparib (Talzenna™)
Veliparib
ANTIBODY (and other) TARGETED DRUG CONJUGATES Antibody Drug Conjugates (ADC)

Targeting mesothelin, MUC16, FRalpha

Anetumab Ravtansine
DMUC4064A
Mirvetuximab Soravtansine
ANGIOGENESIS INHIBITORS VEGF, DLL4 Antagonists Bevacizumab (Avastin™)
Navicixizumab
VEGFR, PDGFR Inhibitors Pazopanib (Votrient™)
Cediranib
ANTI-HORMONEĀ  THERAPY Aromatase Inhibitors Letrozole (Femara™)
SIGNALING PATHWAY INHIBITORS PI3K/AKT/mTOR Pathway

Targeting PI3Kalpha, pan-PI3K, mTOR, TORC1/2

Alpelisib
Everolimus (Afinitor™)
Temsirolimus (Torisel™)
Vistusertib
RAS/RAF/MAPK Pathway

Targeting MEK

Selumetinib
JAK/STAT Pathway

Targeting Stat3

Napabucasin
CELL CYCLE INHIBITORS CDK4/6 Inhibitors Palbociclib (Ibrance™)
CHK1/2 Inhibitors Prexasertib
p53 Activators APR-246
Wee1 Inhibitors Adavosertib
IMMUNOTHERAPY Checkpoint Inhibitors

Targeting CTLA-4, PD-1, PD-L1

Avelumab (Bavencio™)
Durvalumab (Imfinzi™)
Ipilimumab (Yervoy™)
Nivolumab (Opdivo™)
Pembrolizumab (Keytruda™)
Immune Cell Stimulators

Targeting IDO

Epacadostat
Vaccines

Targeting TGFbeta, NY-ESO-1, Survivin

Gemogenovatucel-T (FANG/Vigil™)
NY-ESO-1
DPX-Survivac
Anti-Tumor Antibodies

Targeting FRalpha

Farletuzumab

This diagram shows some of the key cell signaling pathways that are affected by genetic mutations or alterations found in ovarian cancers. The names of proteins encoded by the genes involved in various steps of each pathway are shown. Some proteins promote (indicated by an arrow) a particular step in the pathway and spur cell growth. Other proteins inhibit (indicated by the perpendicular symbol) a step in the pathway and prevent cells from growing and dividing in an uncontrolled way. Some genetic mutations/alterations result in a protein that is more active than it would normally be (shown in green), while others cause the protein to be less active (shown in red). A more active protein that stimulates cell growth or decreased activity of a protein that inhibits these processes can both lead to the uncontrolled growth seen in cancers.